| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bf7439808d578ab8c3698f7560fe4ab |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-10 |
| filingDate |
2013-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2679bc105532c6c10ec64852dc8e77a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06c34c81f69c05befd951e0a34e7f5d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a881aa2dff8b43eaa4db059a6d2cb23 |
| publicationDate |
2014-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014179545-A1 |
| titleOfInvention |
Diagnosis, Prognosis and Identification of Potential Therapeutic Targets of Multiple Myeloma Based on Gene Expression Profiling |
| abstract |
Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10597729-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9650677-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10577656-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9574238-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10752956-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9822419-B2 |
| priorityDate |
2005-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |